NEW YORK, March 1 (GenomeWeb News) - Sigma-Aldrich today announced the completion of its previously announced acquisition of JRH Biosciences.
The acquisition, which was originally announced on Jan. 18, is worth $370 million.
JRH, headquartered in Lenexa, Kan., supplies cell culture and sera products to the biopharmaceutical industry. It had approximately $150 million in sales in 2004, and was expecting 10-percent growth in sales in 2005, Sigma said.
Ten months of JRH's operating results will be added to Sigma-Aldrich's 2005 performance, Sigma said.